Portfolio
Portfolio

Alantos Pharmaceuticals

Developing small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases.

Developing 'best in class' small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases. Apart from the lead product (DPPIV inhibitor in phase I clinical trials) Alantos had 5 programs in various stages of preclinical development.

Alantos Pharmaceuticals was acquired by Amgen in 2007 for US$ 300 million.

  • Industry Biotech
  • History M&A